Management

David Meek brings over 30 years of experience in the biopharmaceutical industry, where he has held key leadership positions across a range of publicly traded and private biotech companies. Most recently, Mr. Meek served as the Chief Executive Officer and a member of the Board of Directors at Mirati Therapeutics, Inc., a commercial-stage oncology biotech company. Mirati was acquired by Bristol Myers Squibb for $5.8 billion.

Prior to his tenure at Mirati, Mr. Meek was the CEO and a Board Member of FerGene, Inc., a private biotech company, from 2020 to 2021. From 2016 to 2020, he led Ipsen, a biopharmaceutical company headquartered in Paris, France, as its Chief Executive Officer and Board Member. Mr. Meek also held significant executive roles, including Executive Vice President and President of Oncology at Baxalta Inc., where he oversaw the oncology division through its acquisition by Shire. Earlier in his career, he served as Chief Commercial Officer at Endocyte, Inc., and held various executive positions at Novartis Pharmaceuticals and Novartis Oncology, following his initial roles at Johnson & Johnson and Janssen Pharmaceuticals.

Currently, Mr. Meek serves on the Boards of Directors for Cullinan Therapeutics Inc. and uniQure N.V., both publicly traded biotech companies. He is also a Board of Councilors member for the University of Southern California Mann School of Pharmacy and Pharmaceutical Sciences. His previous board roles include positions with the Pharmaceutical Research & Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries & Associations, Fusion Pharmaceuticals Inc. (acquired by AstraZeneca), and Entasis Therapeutics Inc. (acquired by Innoviva, Inc.).

Mr. Meek holds a Bachelor of Arts degree from the University of Cincinnati.

Dr. Burns is the scientific founder of Aminex. Mark earned a PhD at the University of Michigan and post-doctoral training in bio-organic chemistry at Rice University. During his over 20 years of experience in biotechnology Mark led the discovery efforts resulting in Aminex’s AMXT 1501/DFMO assets. Mark has obtained 15 U.S. Patents and published 21 scientific papers. He has extensive experience in the fields of medicinal, combinatorial, enzyme inhibitor design, analytical and process chemistry.

Sue Lee, MD is the Chief Medical Officer for Aminex. She is a trained physician scientist who is passionate about translating scientific discoveries into treatments for patients. She has 20 years of industry experience in global clinical development for multiple pharmaceutical, biotech companies including Novartis, BMS, Regeneron, and Astellas where she served as global medical expert leading interdisciplinary teams in the early and late stages of drug development as well as regulatory approvals across multiple assets. In addition to driving clinical programs, Sue simultaneously worked in business development, where she was responsible for scientific clinical diligence and strategy to support enrichment of company pipelines.

Jeff Judson has a cross-cutting responsibility at Aminex in investor recruitment, regulatory oversight, communications, and project management. His career spans 35 years of working on Capitol Hill, studying and influencing public and regulatory policy at all levels of government as a think tank president and later assisting corporations and trade associations to overcome regulatory obstacles.

Greg is currently President of CTM Solutions, LLC, a CMC and clinical trial materials consultancy. He has over 20 years’ experience in GLP, GMP and GCP regulated drug product development, and is a subject matter expert in drug substance synthesis, scale up, process development, and analytical characterization. He also provides regulatory CMC guidance. Greg completed his PhD in Biological Chemistry, at the University of Guelph, Ontario, Canada and postdoctoral training at University of Denver. He has held positions of increasing responsibility at Synthetech, Cell Therapeutics, and SNBL USA. Most recently Dr. Coulter has worked on development teams leading to the FDA approval of the weight loss drug Contrave and the PI3K delta inhibitor Zydelig.